Fineline Cube

Follow:
14455 Articles
CompanyDrug

CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer

CompanyDrug

CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline
CompanyDeals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation
Company

Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation

CompanyDrug

Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio

CompanyDrug

Sichuan Biokin’s Yizekang Receives NMPA Approval as World’s First EGFR×HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma

CompanyDeals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

CompanyDrug

Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy

Shionogi's Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs
CompanyDrug

Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs

Merck's Lipfendra Receives FDA Approval as First Oral PCSK9 Inhibitor for LDL Cholesterol Reduction in Hypercholesterolemia Patients
CompanyDrug

Merck’s Lipfendra Receives FDA Approval as First Oral PCSK9 Inhibitor for LDL Cholesterol Reduction in Hypercholesterolemia Patients

CompanyDeals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Others

DP Technology, Excalipoint Therapeutics Launch AI Antibody Discovery Platform Through Strategic Partnership Focused on T-Cell Engagers